Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Leveraging Metabolic-Driven Treatment Strategies to Target the Origins of NASH
  • CME
  • CE

Credits Available
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Physician Assistants: 1.5 AAPA Category 1 CME Credits
Released: December 7, 2022 Expiration: December 6, 2023
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.
Manal F. Abdelmalek, MD, MPH
Program Director
Rohit Loomba, MD, MHSc
Brent Tetri, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Detail the pathophysiology shared by obesity, type 2 diabetes, and dyslipidemia that contributes to the genesis of NAFLD
  • Summarize key recommendations from the latest clinical care guidelines for NASH regarding early therapeutic interventions aimed at improving metabolic processes for patients with NAFLD/NASH
  • Compare the efficacy and safety outcomes for NASH drugs in late-phase investigations and potential implications in NASH management

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Manal F. Abdelmalek, MD, MPH: consultant: Bristol-Myers Squibb, NGM Biopharmaceuticals, Prometic, TaiwanJ; researcher: Allergan, Bristol-Myers Squibb, Galmed, Genfit, Gilead Sciences, Intercept, Madrigal, NGM Biopharmaceuticals, Novartis, TaiwanJ; fees for non-CME/CE services: Genfit, Intercept.

Faculty

Rohit Loomba, MD, MHSc

Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Rohit Loomba MD, MHSc, has no relevant financial relationships to disclose.
Brent Tetri, MD

Professor of Internal Medicine
Division of Gastroenterology and Hepatology
Saint Louis University
Associate Chair for Clinical Trials
Division of Gastroenterology and Hepatology
SSM-SLUCare
St Louis, Missouri

Brent Tetri, MD: consultant/advisor: 89bio, Akero, Alimentiv, Allergan, Allysta, Alnylam, Amgen, Arrowhead, Axcella, Boehringer Ingelheim, Bristol-Myers Squibb, Coherus, Cymabay, Durect, Enanta, Fortress, GlaxoSmithKline, Genfit, Gilead Sciences, Glympse, Hepeon, HighTide, HistoIndex, Innovo, Intercept, Ionis, LG Chem, Lipocine, Madrigal, Medimmune, Merck, Mirum, NGM Biopharmaceuticals, Novo Nordisk, Novus Therapeutics, pH-Pharma, Sagimet, Target RWE, Theratechnologies; stock options: HepGene; researcher (paid to institution): Allergan, Bristol-Myers Squibb, Celgene, Cirius, Enanta, Genfit, Gilead, HighTide, Intercept, Inventiva, Madrigal, NGM Biopharmaceuticals.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except for Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES, as noted below:

Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES: consultant: Novo Nordisk, Provention Bio, Xeris.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for gastroenterology healthcare professionals, including physicians, nurse practitioners, nurses, and physician associates/physician assistants, and other healthcare professionals who care for patients with NAFLD/NASH.

Goal

The goal of this activity is to improve clinical knowledge and competency among hepatologists, gastroenterologists, hepatology/gastroenterology advanced practice providers, and other healthcare professionals interested in advances in treating NASH.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 6, 2023. PAs should only claim commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 07, 2022, through December 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Leveraging Metabolic-Driven Treatment Strategies to Target the Origins of NASH
  • CME
  • CE

Loading...
Experts provide a review of therapeutic interventions for NAFLD/NASH, including key recommendations from the latest clinical care guidelines and the safety and efficacy of emerging agents.
Manal F. Abdelmalek, MD, MPH
Program Director
Rohit Loomba, MD, MHSc
Brent Tetri, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Physician Assistants: 1.5 AAPA Category 1 CME Credits
Released: December 7, 2022 Expiration: December 6, 2023

Related Content

A quick reference guide to identify obesity specialists in or near Kansas City, from Clinical Care Options (CCO)

Released: January 23, 2023

A quick reference guide to identify obesity specialists in Indiana, from Clinical Care Options (CCO)

Released: January 20, 2023

Expert answers to learner questions from a live symposium with simulcast about strategies for a proactive approach to obesity management, from Clinical Care Options (CCO)

Caroline Apovian, MD Ken Fujioka, MD Released: January 13, 2023

Learn from an expert about the use of setmelanotide for hunger and weight management in pediatric patients with Bardet-Biedl syndrome, from Clinical Care Options (CCO)

Stephanie Sisley, MD Released: January 9, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Novo Nordisk Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings